Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials
Abstract
:1. Introduction
2. The Case for Vaccines to Prevent Coccidioidomycosis
3. Past Attempts to Create a Coccidioidal Vaccine
4. The Discovery of CPS1 as a Critical Gene for Spherule Maturation
5. The Pre-Clinical Safety Profile of Δcps1
6. Vaccination with Δcps1 Provides Robust Protection against Experimental Pulmonary Coccidioidal Infection in Mice and Dogs
7. Mechanisms of Protection
8. Development Plan to Initiate Human Studies
9. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Blackwell, M. The fungi: 1, 2, 3 … 5.1 million species? Am. J. Bot. 2011, 98, 426–438. [Google Scholar] [CrossRef] [PubMed]
- Adamian, C.M.C.; Mota, M.A.D.L.; Martins, A.A.F.; Aragão, M.C.; Carvalho, M.S.; Meneses, G.C.; Júnior, G.B.D.S.; Leitão, T.D.M.J.S.; Daher, E.D.F. Progressive disseminated histoplasmosis in HIV-positive patients. Int. J. STD AIDS 2022, 33, 544–553. [Google Scholar] [CrossRef] [PubMed]
- Benedict, K.; Toda, M.; Jackson, B.R. Revising conventional wisdom about histoplasmosis in the United States. Open Forum Infect. Dis. 2021, 8, ofab306. [Google Scholar] [CrossRef] [PubMed]
- Cari, E.V.; Leedy, N.; Ribes, J.A.; Soria, J.; Myint, T. Risk factors of severe blastomycosis and comparison of diagnosis and outcomes between immunocompetent and immunocompromised patients. Mycoses 2022, 65, 239–246. [Google Scholar] [CrossRef] [PubMed]
- Ireland, M.; Klumb, C.; Smith, K.; Scheftel, J. Blastomycosis in Minnesota, USA, 1999–2018. Emerg. Infect. Dis. 2020, 26, 866–875. [Google Scholar] [CrossRef]
- Blair, J.E.; Ampel, N.M.; Hoover, S.E. Coccidioidomycosis in selected immunosuppressed hosts. Med. Mycol. 2018, 57, S56–S63. [Google Scholar] [CrossRef]
- Oliveira, L.V.N.; Wang, R.; Specht, C.A.; Levitz, S.M. Vaccines for human fungal diseases: Close but still a long way to go. NPJ Vaccines 2021, 6, 33. [Google Scholar] [CrossRef]
- Laniado-Laborin, R.; Arathoon, E.G.; Canteros, C.; Muniz-Salazar, R.; Rendon, A. Coccidioidomycosis in Latin America. Med. Mycol. 2019, 57 (Suppl. S1), S46–S55. [Google Scholar] [CrossRef]
- McCotter, O.Z.; Benedict, K.; Engelthaler, D.M.; Komatsu, K.; Lucas, K.D.; Mohle-Boetani, J.C.; Oltean, H.; Vugia, D.; Chiller, T.M.; Cooksey, G.L.S.; et al. Update on the epidemiology of coccidioidomycosis in the United States. Med. Mycol. 2019, 57 (Suppl. S1), S30–S40. [Google Scholar] [CrossRef]
- Benedict, K.; Ireland, M.; Weinberg, M.P.; Gruninger, R.J.; Weigand, J.; Chen, L.; Perez-Lockett, K.; Bledsoe, C.; Denny, L.; Cibulskas, K.; et al. Enhanced surveillance for coccidioidomycosis, 14 US States, 2016. Emerg. Infect. Dis. 2018, 24, 1444–1452. [Google Scholar] [CrossRef] [Green Version]
- Turabelidze, G.; Aggu-Sher, R.K.; Jahanpour, E.; Hinkle, C.J. Coccidioidomycosis in a state where it is not known to be endemic—Missouri, 2004–2013. MMWR Morb. Mortal. Wkly. Rep. 2015, 64, 636–639. [Google Scholar] [PubMed]
- Khan, M.A.; Brady, S.; Komatsu, K.K. Testing for coccidioidomycosis in emergency departments in Arizona. Med. Mycol. 2018, 56, 3. [Google Scholar] [CrossRef] [Green Version]
- Chang, D.C.; Anderson, S.; Wannemuehler, K.; Engelthaler, D.M.; Erhart, L.; Sunenshine, R.H.; Burwell, L.A.; Park, B.J. Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg. Infect. Dis. 2008, 14, 1053–1059. [Google Scholar] [CrossRef] [PubMed]
- Wieden, M.A.; Lundergan, L.L.; Blum, J.; Delgado, K.L.; Coolbaugh, R.; Howard, R.; Peng, T.; Pugh, E.; Reis, N.; Theis, J.; et al. Detection of coccidioidal antibodies by 33-kDa spherule antigen, Coccidioides EIA, and standard serologic tests in sera from patients evaluated for coccidioidomycosis. J. Infect. Dis. 1996, 173, 1273–1277. [Google Scholar] [CrossRef] [PubMed]
- Freedman, M.; Anderson, S.; Benedict, K.; McCotter, O.; Derado, G.; Hoekstra, R. Preliminary Estimates of Annual Burden of Coccidioidomycosis in the United States, 2010–2014. Available online: http://coccistudygroup.com/wp-content/uploads/2017/11/CSG-61st-Annual-Proceedings-11-27-17.pdf (accessed on 8 August 2022).
- Tsang, C.A.; Anderson, S.M.; Imholte, S.B.; Erhart, L.M.; Chen, S.; Park, B.J.; Christ, C.; Komatsu, K.K.; Chiller, T.; Sunenshine, R.H. Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007–2008. Emerg. Infect. Dis. 2010, 16, 1738–1744. [Google Scholar] [CrossRef] [PubMed]
- Galgiani, J.N.; Blair, J.E.; Ampel, N.M.; Thompson, G.R. Treatment for early, uncomplicated coccidioidomycosis: What is success? Clin. Infect. Dis. 2020, 70, 2008–2012. [Google Scholar] [CrossRef]
- Galgiani, J.N.; Ampel, N.M.; Blair, J.E.; Catanzaro, A.; Geertsma, F.; Hoover, S.E.; Johnson, R.H.; Kusne, S.; Lisse, J.; MacDonald, J.D.; et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin. Infect. Dis. 2016, 63, e112–e146. [Google Scholar] [CrossRef] [Green Version]
- Benedict, K.; Whitham, H.K.; Jackson, B.R. Economic burden of fungal diseases in the United States. Open Forum Infect. Dis. 2022, 9, ofac097. [Google Scholar] [CrossRef]
- Wilson, L.; Ting, J.; Lin, H.; Shah, R.; MacLean, M.; Peterson, M.W.; Stockamp, N.; Libke, R.; Brown, P. The rise of Valley Fever: Prevalence and cost burden of coccidioidomycosis infection in California. Int. J. Environ. Res. Public Health 2019, 16, 1113. [Google Scholar] [CrossRef] [Green Version]
- Grizzle, A.J.; Wilson, L.; Nix, D.E.; Galgiani, J.N. Clinical and economic burden of Valley Fever in Arizona: An incidence-based cost-of-illness analysis. Open Forum Infect. Dis. 2021, 8, ofaa623. [Google Scholar] [CrossRef]
- Salkin, D.; Said, A. Reinfection with coccidioidomycosis. Clin. Infect. Dis. 1993, 17, 1066. [Google Scholar] [CrossRef] [PubMed]
- Smith, C.E.; Whiting, E.G.; Baker, E.E.; Rosenberger, H.G.; Beard, R.R.; Saito, M.T. The use of coccidioidin. Am. Rev. Tuberc. 1948, 57, 330–360. [Google Scholar]
- Smith, C.E.; Pappagianis, D.; Levine, H.B.; Saito, M.T. Human coccidioidomycosis. Bacteriol. Rev. 1961, 25, 310–320. [Google Scholar] [CrossRef] [PubMed]
- Pappagianis, D.; Levine, H.B.; Smith, C.E.; Berman, R.J.; Kobayashi, G.S. Immunization of mice with viable Coccidioides immitis. J. Immunol. 1961, 86, 28–34. [Google Scholar] [PubMed]
- Fierer, J.; Waters, C.; Walls, L. Both CD4+ and CD8+ T cells can mediate vaccine-induced protection against Coccidioides immitis infection in mice. J. Infect. Dis. 2006, 193, 1323–1331. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vogel, R.A.; Fetter, B.F.; Conant, N.F.; Lowe, E.P. Preliminary studies on artificial active immunization of guinea pigs against respiratory challenge with Coccidioides immitis. Am. Rev. Tuberc. 1954, 70, 498–503. [Google Scholar] [PubMed]
- Converse, J.L. Growth of spherules of Coccidioides immitis in a chemically defined liquid medium (22144). Proc. Soc. Exp. Biol. Med. 1955, 90, 709–711. [Google Scholar] [CrossRef]
- Converse, J.L. Effect of surface active agents on endosporulation of Coccidioides immitis in a chemically defined medium. J. Bacteriol. 1957, 74, 106–107. [Google Scholar] [CrossRef] [Green Version]
- Converse, J.L.; Besemer, A.R. Nutrition of the parasitic phase of Coccidioides Immitis in a chemically defined liquid medium. J. Bacteriol. 1959, 78, 231–239. [Google Scholar] [CrossRef] [Green Version]
- Levine, H.B. Purification of the spherule-endospore phase of Coccidioides Immitis. Sabouraudia 1961, 1, 112–115. [Google Scholar] [CrossRef]
- Levine, H.B.; Cobb, J.M.; Smith, C.E. Immunogenicity of spherule-endospore vaccines of Coccidioides immitis for mice. J. Immunol. 1961, 87, 218–227. [Google Scholar] [PubMed]
- Kong, Y.C.; Levine, H.B.; Madin, S.H.; Smith, C.E. Fungal Multiplication and histopathologic changes in vaccinated mice infected with Coccidioides Immitis. J. Immunol. 1964, 92, 779–790. [Google Scholar] [PubMed]
- Levine, H.B.; Pappagianis, D.; Cobb, J.M. Development of vaccines for coccidioidomycosis. Mycopathologia 1970, 41, 177–185. [Google Scholar] [CrossRef]
- Williams, P.L.; Sable, D.L.; Sorgen, S.P.; Pappagianis, D.; Levine, H.B.; Brodine, S.K.; Brown, B.W.; Grumet, F.C.; Stevens, D.A. Immunologic responsiveness and safety associated with the Coccidioides immitis spherule vaccine in volunteers of White, Black, and Filipino ancestry. Am. J. Epidemiol. 1984, 119, 591–602. [Google Scholar] [CrossRef] [PubMed]
- Williams, P.L.; Brown, B.W., Jr.; Cunningham, R.T.; Einstein, H.; Ellsworth, R.; Galgiani, J.N.; Hampson, C.R.; Holeman, C.W.; Johnson, R.H.; Larwood, T.R.; et al. Further Assessment of the Morbidity Associated with the Killed Coccidioides immitis Spherule Vaccine in Humans; National Foundation for Infectious Diseases: Washington, DC, USA, 1985; pp. 339–346. [Google Scholar]
- Pappagianis, D.; Valley Fever Vaccine Study Group. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. Am. Rev. Respir. Dis. 1993, 148, 656–660. [Google Scholar] [CrossRef]
- Gifford, M.A.; Buss, W.C.; Douds, R.J.; Miller, H.E.; Tupper, R.B. Data on coccidioides fungus infection, Kern County. Kern Cty. Dept. Public Health Ann. Rep. 1937, 39–54. [Google Scholar]
- Dickson, E.C.; Gifford, M.A. Coccidioides infection (Coccidioidomycosis). II. The primary type of infection. Arch. Intern. Med. 1938, 62, 853–871. [Google Scholar] [CrossRef]
- Hector, R.; Rutherford, G.W. The public health need and present status of a vaccine for the prevention of coccidioidomycosis. Ann. N. Y. Acad. Sci. 2007, 1111, 259–268. [Google Scholar] [CrossRef]
- Shubitz, L.F.; Yu, J.-J.; Hung, C.-Y.; Kirkland, T.N.; Peng, T.; Perrill, R.; Simons, J.; Xue, J.; Herr, R.A.; Cole, G.T.; et al. Improved protection of mice against lethal respiratory infection with Coccidioides posadasii using two recombinant antigens expressed as a single protein. Vaccine 2006, 24, 5904–5911. [Google Scholar] [CrossRef]
- Galgiani, J.N. Vaccines to prevent systemic mycoses: Holy grails meet translational realities. J. Infect. Dis. 2008, 197, 938–940. [Google Scholar] [CrossRef]
- Xue, J.; Chen, X.; Selby, D.; Hung, C.Y.; Yu, J.J.; Cole, G.T. A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis. Infect. Immun. 2009, 77, 3196–3208. [Google Scholar] [CrossRef] [Green Version]
- Lu, S.-W.; Kroken, S.; Lee, B.-N.; Robbertse, B.; Churchill, A.C.L.; Yoder, O.C.; Turgeon, B.G. A novel class of gene controlling virulence in plant pathogenic ascomycete fungi. Proc. Natl. Acad. Sci. USA 2003, 100, 5980–5985. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nitta, Y.; Yamazaki, D.; Sugie, A.; Hiroi, M.; Tabata, T. DISCO Interacting Protein 2 regulates axonal bifurcation and guidance of Drosophila mushroom body neurons. Dev. Biol. 2017, 421, 233–244. [Google Scholar] [CrossRef]
- Ouchi, N.; Asaumi, Y.; Ohashi, K.; Higuchi, A.; Sono-Romanelli, S.; Oshima, Y.; Walsh, K. DIP2A functions as a FSTL1 receptor. J. Biol. Chem. 2010, 285, 7127–7134. [Google Scholar] [CrossRef] [Green Version]
- Tanaka, M.; Murakami, K.; Ozaki, S.; Imura, Y.; Tong, X.-P.; Watanabe, T.; Sawaki, T.; Kawanami, T.; Kawabata, D.; Fujii, T.; et al. DIP2 disco-interacting protein 2 homolog A (Drosophila) is a candidate receptor for follistatin-related protein/follistatin-like 1—Analysis of their binding with TGF-beta superfamily proteins. FEBS J. 2010, 277, 4278–4289. [Google Scholar] [CrossRef]
- Narra, H.P.; Shubitz, L.F.; Mandel, M.A.; Trinh, H.T.; Griffin, K.; Buntzman, A.S.; Frelinger, J.A.; Galgiani, J.N.; Orbach, M.J. A Coccidioides posadasii CPS1 deletion mutant is avirulent and protects mice from lethal infection. Infect. Immun. 2016, 84, 3007–3016. [Google Scholar] [CrossRef] [Green Version]
- Mandel, M.A.; Beyhan, S.; Voorhies, M.; Shubitz, L.F.; Galgiani, J.N.; Orbach, M.J.; Sil, A. The WOPR family protein Ryp1 is a key regulator of gene expression, development, and virulence in the thermally dimorphic fungal pathogen Coccidioides posadasii. PLoS Pathog. 2022, 18, e1009832. [Google Scholar] [CrossRef]
- Jones, D.T.; Thornton, J.M. The impact of AlphaFold2 one year on. Nat. Methods 2022, 19, 15–20. [Google Scholar] [CrossRef]
- Muhammed, M.; Feldmesser, M.; Shubitz, L.F.; Lionakis, M.S.; Sil, A.; Wang, Y.; Glavis-Bloom, J.; Lewis, R.E.; Galgiani, J.N.; Casadevall, A.; et al. Mouse models for the study of fungal pneumonia: A collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus. Virulence 2012, 3, 329–338. [Google Scholar] [CrossRef] [Green Version]
- Shubitz, L.F.; Dial, S.M.; Perrill, R.; Casement, R.; Galgiani, J.N. Vaccine-induced cellular immune responses differ from innate responses in susceptible and resistant strains of mice infected with Coccidioides posadasii. Infect. Immun. 2008, 76, 5553–5564. [Google Scholar] [CrossRef] [Green Version]
- Cox, R.A.; Magee, D.M. Coccidioidomycosis: Host response and vaccine development. Clin. Microbiol. Rev. 2004, 17, 804–839, table of contents. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shultz, L.D.; Brehm, M.A.; Garcia-Martinez, J.V.; Greiner, D.L. Humanized mice for immune system investigation: Progress, promise and challenges. Nat. Rev. Immunol. 2012, 12, 786–798. [Google Scholar] [CrossRef] [PubMed]
- Swindle, M.M.; Makin, A.; Herron, A.J.; Clubb, F.J., Jr.; Frazier, K.S. Swine as models in biomedical research and toxicology testing. Vet. Pathol. 2012, 49, 344–356. [Google Scholar] [CrossRef] [PubMed]
- Dawson, H.D.; Loveland, J.E.; Pascal, G.; Gilbert, J.G.; Uenishi, H.; Mann, K.M.; Sang, Y.; Zhang, J.; Carvalho-Silva, D.; Hunt, T.; et al. Structural and functional annotation of the porcine immunome. BMC Genom. 2013, 14, 332. [Google Scholar] [CrossRef] [Green Version]
- Hein, W.R.; Griebel, P.J. A road less travelled: Large animal models in immunological research. Nat. Rev. Immunol. 2003, 3, 79–84. [Google Scholar] [CrossRef]
- Mair, K.H.; Sedlak, C.; Kaser, T.; Pasternak, A.; Levast, B.; Gerner, W.; Saalmuller, A.; Summerfield, A.; Gerdts, V.; Wilson, H.L.; et al. The porcine innate immune system: An update. Dev. Comp. Immunol. 2014, 45, 321–343. [Google Scholar] [CrossRef]
- Meurens, F.; Summerfield, A.; Nauwynck, H.; Saif, L.; Gerdts, V. The pig: A model for human infectious diseases. Trends Microbiol. 2012, 20, 50–57. [Google Scholar] [CrossRef]
- Mills, K.H.; Gerdts, V. Mouse and pig models for studies of natural and vaccine-induced immunity to Bordetella pertussis. J. Infect. Dis. 2014, 209 (Suppl. S1), S16–S19. [Google Scholar] [CrossRef] [Green Version]
- Navarro-Alvarez, N.; Goncalves, B.M.M.; Andrews, A.R.; Sachs, D.H.; Huang, C.A. A CFA-Induced model of inflammatory skin disease in miniature swine. Int. J. Inflamm. 2018, 2018, 6916920. [Google Scholar] [CrossRef] [Green Version]
- Shubitz, L.F.; Powell, D.A.; Trinh, H.T.; Lewis, M.L.; Orbach, M.J.; Frelinger, J.A.; Galgiani, J.N. Viable spores of Coccidioides posadasii Deltacps1 are required for vaccination and provide long lasting immunity. Vaccine 2018, 36, 3375–3380. [Google Scholar] [CrossRef] [Green Version]
- Shubitz, L.F.; Robb, E.J.; Powell, D.A.; Bowen, R.A.; Bosco-Lauth, A.; Hartwig, A.; Porter, S.M.; Trinh, H.; Moale, H.; Bielefeldt-Ohmann, H.; et al. Δcps1 vaccine protects dogs against experimentally induced coccidioidomycosis. Vaccine 2021, 39, 6894–6901. [Google Scholar] [CrossRef] [PubMed]
- Shubitz, L.F. Comparative aspects of coccidioidomycosis in animals and humans. Ann. N. Y. Acad. Sci. 2007, 1111, 395–403. [Google Scholar] [CrossRef] [PubMed]
- Hung, C.Y.; Hsu, A.P.; Holland, S.M.; Fierer, J. A review of innate and adaptive immunity to coccidioidomycosis. Med. Mycol. 2019, 57 (Suppl. S1), S85–S92. [Google Scholar] [CrossRef] [PubMed]
- Kirkland, T.N.; Fierer, J. Coccidioides immitis and posadasii; A review of their biology, genomics, pathogenesis, and host immunity. Virulence 2018, 9, 1426–1435. [Google Scholar] [CrossRef] [Green Version]
- Powell, D.A.; Hsu, A.P.; Butkiewicz, C.D.; Trinh, H.T.; Frelinger, J.A.; Holland, S.M.; Galgiani, J.N.; Shubitz, L.F. Vaccine protection of mice with primary immunodeficiencies against disseminated coccidioidomycosis. Front. Cell. Infect. Microbiol. 2021, 11, 790488. [Google Scholar] [CrossRef]
- Powell, D.A.; Hsu, A.P.; Shubitz, L.F.; Butkiewicz, C.D.; Moale, H.; Trinh, H.T.; Doetschman, T.; Georgieva, T.G.; Reinartz, D.M.; Wilson, J.E.; et al. Mouse model of a human STAT4 point mutation that predisposes to disseminated coccidiomycosis. ImmunoHorizons 2022, 6, 130–143. [Google Scholar] [CrossRef]
- Hsu, A.P.; Davis, J.; Chaput, A.L.; Powell, D.; Pouladi, N.; Lussier, Y.; Fierer, J.; Frelinger, J.; Galgiani, J.N.; Lionakis, M.; et al. 42. Common population variants cause susceptibility to disseminated coccidioidomycosis. Open Forum Infect. Dis. 2020, 7 (Suppl. S1), S22–S23. [Google Scholar] [CrossRef]
- Peng, T.; Zong, Y.; Johnson, M.D.; Menghani, S.V.; Lewis, M.L.; Galgiani, J.N. A quantitative enzyme-linked immunoassay (ELISA) to approximate complement-fixing antibody titers in serum from patients with coccidioidomycosis. Diagn. Microbiol. Infect. Dis. 2021, 99, 115198. [Google Scholar] [CrossRef]
- Dobson, H.E.; Dias, L.D.S.; Kohn, E.M.; Fites, S.; Wiesner, D.L.; Dileepan, T.; Kujoth, G.C.; Abraham, A.; Ostroff, G.R.; Klein, B.S.; et al. Antigen discovery unveils resident memory and migratory cell roles in antifungal resistance. Mucosal Immunol. 2020, 13, 518–529. [Google Scholar] [CrossRef]
- Wuthrich, M.; Ersland, K.; Sullivan, T.; Galles, K.; Klein, B.S. Fungi subvert vaccine T cell priming at the respiratory mucosa by preventing chemokine-induced influx of inflammatory monocytes. Immunity 2012, 36, 680–692. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galgiani, J.N.; Shubitz, L.F.; Orbach, M.J.; Mandel, M.A.; Powell, D.A.; Klein, B.S.; Robb, E.J.; Ohkura, M.; Seka, D.J.; Tomasiak, T.M.; et al. Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials. J. Fungi 2022, 8, 838. https://doi.org/10.3390/jof8080838
Galgiani JN, Shubitz LF, Orbach MJ, Mandel MA, Powell DA, Klein BS, Robb EJ, Ohkura M, Seka DJ, Tomasiak TM, et al. Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials. Journal of Fungi. 2022; 8(8):838. https://doi.org/10.3390/jof8080838
Chicago/Turabian StyleGalgiani, John N., Lisa F. Shubitz, Marc J. Orbach, M. Alejandra Mandel, Daniel A. Powell, Bruce S. Klein, Edward J. Robb, Mana Ohkura, Devin J. Seka, Thomas M. Tomasiak, and et al. 2022. "Vaccines to Prevent Coccidioidomycosis: A Gene-Deletion Mutant of Coccidioides Posadasii as a Viable Candidate for Human Trials" Journal of Fungi 8, no. 8: 838. https://doi.org/10.3390/jof8080838